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ABSTRACT
Cordyceps sinensis, an entomogenous fungus used in traditional Chinese medicine, exhibits very broad biological and pharmacological actions in hepatic, renal, cardiovascular, and immunologic systems as well as anticancer activity. Pharmacological functions of
Cordyceps are primarily due to the bioactive polysaccharides, modified nucleosides, and cyclosporin-like metabolites produced by this
fungus and related species. The beneficial effects on renal and hepatic function and immunomodulation-related antitumor activities are
most promising and deserve great attention. Many previous studies used fruiting bodies, but recently an increasing number of studies have
used cultured mycelia in investigations. It is difficult to determine if the same bioactive ingredients exist in fruiting bodies and cultured
mycelia and contribute to the pharmacological actions reported in the literature. More mechanism-based, disease-oriented pharmacological studies are required to ensure clinical efficacy for particular diseases. Adjuvant therapy using C. sinensis for immune function disturbances, cancer, and renal failure is possible if double-blind, randomized placebo-control clinical studies show the efficacy of this herb.
Key words: Cordyceps sinensis, anticancer activities, hepatic function, renal function, immunomodulation, polysaccharides, modified
nucleosides

INTRODUCTION
Cordyceps sinensis (Berk.) Sacc. (abbreviated as CS) is
an entomogenous fungus that has long been used as a
Chinese medicine and tonic foods. The herbal product is
composed of the fruiting body and its host larva. Many recent
pharmacological studies have used fermented mycelial products. CS in its wild form and mycelial products exhibits a
broad spectrum of biological and pharmacological actions in
hepatic, renal, cardiovascular, immunologic, and nervous
systems as well as anticancer activity(1-3). The effects of CS
on the renal system and its modulatory effect on the host
immune system deserve great attention. Active principles in
Cordyceps are primarily polysaccharides, modified nucleosides, and cyclosporin-like metabolites produced by this
medicinal fungus. According to the physicochemical properties of natural products, aqueous preparations (polysaccharide containing) and alcohol extracts (polysaccharidedevoid) of CS are most commonly used for in vitro and in
vivo studies. Only a few reports use pure compounds from
CS for pharmacological studies. In quite a few studies, the
origin and taxonomy of Cordyceps products are not clearly
addressed. This article intends to review the pharmacological
functions of CS and related species based on the recent
advances in the literature and from our laboratories (Table 1).

PHARMACOLOGICAL FUNCTIONS
OF CORDYCEPS
* Author for correspondence. Tel: 02-28712121 ext. 3363;
Fax: 02-28751562; E-mail: msshiao@vghtpe.gov.tw

Hepatic Function
The mycelial extract of cultured CS stimulates hepatic
Table 1. Major pharmacological functions of Cordyceps sinensis
Hepatic function
a. Stimulation of energy metabolism
b. Activation of Kupffer cell function: water-soluble fraction
c. Reduction of post-hepatitic cirrhosis: unknown
Renal function
a. Reduction of aminoglycoside-induced nephrotoxicity
b. Reduction of hematuria and proteinuria in experimental IgA
nephropathy (IgAN): low MW sterols (CS-H1-A)
Endocrine and steroid system
a. Stimulation of corticosteroid production in animals: unknown
b. Stimulation of corticosterone production by cultured rat adrenal
cells: water-soluble fraction
Cardiovascular function
a. Inhibition of platelet aggregation: adenosine and other related
nucleosides
b. Reduction of aconitine, BaCl2 and ouabain-induced arrhythmia:
low MW metabolites
Anticancer activities
a. Sterols and their glucosides
b. Low MW metabolites other than cordycepin
c. Modified nucleosides
d. Antitumor function via immunopotentiation and cytokine production: polysaccharides
Immunomodulation
a. Immunopotentiation: polysaccharides
b. Immunosuppression: cyclosporine-like metabolites and others
Hypoglycemic activity in STZ-induced diabetes
Polysaccharides
Erythropoiesis and hemopoiesis
Active ingredient unknown
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energy metabolism in mice. In an animal experiment, mice
were given the CS extract (200 mg/kg/day, p.o.) for 3 weeks
and in vivo 31P NMR spectra of liver were acquired weekly
for 3 weeks. A consistent increase in the [ATP]/[Pi] ratio,
which represents the high-energy state, was observed in the
CS treated mice. No steatosis, necrosis, inflammation, or
fibrosis in the liver was observed in the specimens from CS
extract-treated animals(4).
Oral administration of the water extracts of CS (WECS)
activates in vivo Kupffer cell function in rats(5). After receiving a single i.v. injection of a colloidal carbon solution, the
clearance rate from the blood was measured. Test animals
were administered daily with WECS (p.o. at 200 mg/kg) for
25 days until the day before the colloidal carbon injection.
The half-life of the colloidal carbon in the blood was significantly shorter in the WECS-treated group. The results indicate that stimulation of the Kupffer cell function may partly
explain the anti-metastatic action of CS. The stimulating
effects of CS, and rat serum containing the same medicine,
on IL-1, IFN and TNF produced by Kupffer cells have also
been studied in rats(6). The levels of IL-1, IFN, and TNF,
especially those of IL-1 and IFN, produced by cultured rat
Kupffer cells are increased by CS, or the drug serum (DS)
from animals fed on CS. Treatment of Paecilomyces sinensis
(i.g. 3g/kg/dx14) increases SOD in the liver of mice(7). P.
sinensis inhibits the production of lipid hydroperoxides and
increases the amount of SOD in liver homogenates of mice in
vitro. P. sinensis also increases glutathione peroxidase in the
liver homogenates of mice.
Disorder of the immune function is one of the important
causes of liver cell necrosis, inflammatory cell infiltration,
and fibroblastic proliferation. The modulatory effect of cultivated Cordyceps hyphae (CH) on immuno-dysfunction of
post-hepatitic cirrhosis of patients (n=65) has been reported(8). The restrained cellular immune functions, including the
rate of lymphocyte transformation, the NK cell function, and
the CD8+ and CD4+ cells, in the patients’ group are lower
than those in the healthy group. The CD8+ cell count is positively correlated with the lymphocyte transformation rate and
the humoral immune hyperfunction, revealing that the levels
of IgG, IgA, ssIgA and CIC of the patients are abnormally
high. The C3 is negatively correlated with that of CIC. After
CH treatment, the rate of transformation, function of NK cell,
CD8+, CD4+ cells and ratio of CD4+/CD8+ are improved.
The levels of IgG, IgA, ssIgA and CIC are reduced, while
those of C4 and C3 are increased. In summary, CH treatment
modulates the cellular immune function, inhibits the humoral
immune hyperfunction, and increases the serum complement
level in the patients with post-hepatitic cirrhosis.
The short-term curative effect of cultured mycelia of CS
in chronic hepatitis B (HBV) has been demonstrated(9).
Treatment of CS improves the liver function, promotes negative transfer HBsAg, raises plasma albumin, resists high γglobulin, and adjusts body immuno-competence in HBV
patients (n=33). A combination recipe (composed of Semen
Persicae, Cordyceps, Radix Salviae miltiorrhizae, Pollen
pini, and others) in the treatment of 40 posthepatitic cirrhosis

patients has been demonstrated(10). Elevation of lowered
plasma branched-chain amino acid to aromatic amino acid
ratio has been observed. CS treatment reduces the raised levels of serum laminin and hyaluronic acid. Treated patients
also exhibit increased levels of CD3+, CD4+, CD4+/CD8+
ratio, NK cells activity and complement C3 and lower levels
of IgG and IgM in serum. The combination therapy, which
contains CS, is beneficial in the treatment of post-hepatitic
cirrhosis. However, the contribution of CS in this combination therapy remains unknown.

Renal Function
Many studies have indicated that CS treatment reduces
nephrotoxicity caused by aminoglycoside. The effect of CS
on gentamycin-induced nephrotoxicity has been elucidated(11). CS administration reduces BUN, SCr, sodium excretion, and urinary nephro-aminoglycosidase (NAGase)
together with less severity of histopathological changes. CS
also promotes an earlier recovery of renal oxygen consumption, inulin clearance, and sodium absorption in isolated perfused kidney of intoxicated rats. Possible mechanisms of CS
on aminoglycoside-induced nephrotoxicity include accelerating tubular cell regeneration, protecting the sodium pump
activity of tubular cells, attenuating the tubular cell lysosome
hyperfunction (stimulated by phagocytosis of aminogly
coside), decreasing lipid peroxidation in response to injury,
and reducing the Ca++ content. CS also reduces aminoglycoside-induced acute renal failure (ARF) in rats(12). ARF model
of rats was induced by i.p. injection of either gentamycin or
kanamycin. Simultaneous administration of CS with gentamycin protects the proximal tubular cells from gentamycintoxicity. After the establishment of kanamycin nephrotoxic
ARF, CS treatment causes an earlier recovery from ARF. The
possible mechanisms of CS on ARF include protection of
tubular cell sodium pump activity, attenuation of tubular cell
lysosome overfunction stimulated by phagocytosis of aminoglycoside, and reduction of tubular cell lipid peroxidation in
response to toxic injury(12). The protective effect of CS on
aminoglycoside nephrotoxicity in elderly patients has also
been observed. Patient groups receiving amikacin sulfate for
6 days were administered with CS or placebo for 7 days. CStreated group developed less prominent nephrotoxicity as
determined by less urinary NAGase and β-microglobulin(13).
The protective effect of CS on cyclosporin A (CsA)
nephrotoxicity (CsA-Nx) has also been studied in rats(14). On
the 15th day after receiving CsA, animals developed prominent vacuolation and necrosis in proximal tubular cells and
mitochondria swelling. Severe vacuolation (90%) and necrosis appear in proximal tubular cells at different stages of
chronic CsA-Nx. Interstitial edema with mild fibrosis also
occurs. The epithelial cell areas of tubules and glomeruli are
smaller in the CsA group than those in the CS group. These
results indicate that CS protects the kidney from CsA-Nx and
ameliorates the glomerular and interstitial injuries.
Amelioration of cyclosporin nephrotoxicity by CS in kidneytransplanted recipients has also been reported(15). The effect
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of CS on cellular immunity in rats with chronic renal insufficiency has also been demonstrated(16). Chronic renal failure
(CRF) was induced in Wistar rats by 5/6 nephrectomy. CS
shows a mitogenic effect on spleen lymphocytes and increases IL-2 production from splenocytes of CRF rats. CS treatment also decreases the levels of BUN and serum creatinine
and increases the level of hemoglobin.
CS also stimulates tubular epithelial cell growth(17).
Primary cultured rat tubular epithelium was used to investigate the effect of CS on cellular proliferation and metabolism. Incorporation of 3H-TdR into DNA is increased indicating that CS promotes DNA synthesis and cell proliferation. In association with the beneficial effect to reduce
aminoglycoside nephrotoxity in vivo, CS may enhance the
regeneration of injured tubular cells.
A recent hypothesis suggests that the pathogenesis of
immunoglobulin A nephropathy (IgAN) involves the deposition of nephritogenic IgA immune complexes (IgAIC) in the
kidney that stimulates resting mesangial cells to release
cytokines and growth factors. These cytokines and growth
factors cause mesangial cell proliferation and release matrix,
chemical mediators that lead to the glomerular injury. In cultured human mesangial cells (HMC) stimulation with IL-1
plus IL-6 causes mesangial cell proliferation and increases
production of chemical mediators and superoxide anion.
Active fractions and a natural product (CS-H1-A) from CS
inhibit the activated human mesangial cell proliferation in
this model(18). The crude methanolic extract from fruiting
bodies of CS inhibits HMC activation. The fruiting body
extracts were further separated by silica gel column chromatography. A fraction (F-2) inhibits the HMC activation by
IL-1 plus IL-6. In IgAN mouse model, R36A (Pneumococcal
C-polysaccharide purified from Streptococcus pneumoniae)
as antigen and anti-R36A IgA MAb form nephritogenic IgAIC, which induces hematuria and proteinuria in mice with
IgA deposition in the mesangial area. Feeding with F-2 (1%
w/w in the diet) reduces hematuria and proteinuria together
with histopathologic improvement. Treatment with a purified
compound (CS-H1-A) from F-2 suppresses the activated
HMC and alleviates IgAN with histologic improvement. The
study suggests that CS is a potential regimen for the treatment of patients with IgAN(18).

Endocrine and Steroid Hormones
Testosterone-like metabolites and libido-promoting
activity have been suspected in CS and in the consumption of
CS and CS-containing products for years. However, no direct
evidence in the scientific literature is strong enough to link
the known CS metabolites to the function. CS stimulates corticosteroid production in animal models. Recently, the action
mechanism of CS directly on the adrenal glands or indirectly
via the hypothalamus-pituitary axis has been investigated.
The effect of a water-soluble extract of CS on steroidogenesis and capsular morphology of lipid droplets in cultured rat
adrenocortical cells has been demonstrated(19). The corticosterone production by adrenal cells, determined by RIA, is

increased by CS treatment. The stimulatory effect can be
seen 1 hr after CS treatment and maintained for up to 24 hr.
Lipid droplets within cells are smaller and fewer. Immunostaining with a MAb, A2, a specific marker for the lipid
droplet capsule, demonstrates that detachment of the capsule
from the lipid droplet occurs in CS-treated cells. The period
required for decapsulation is inversely related to CS in a
dose-dependent manner. The CS-induced steroidogenesis is
different from that for ACTH, since intracellular cAMP level
is not increased in CS-treated cells. Combined treatment with
calphostin C, a PKC inhibitor, blocks the effect of CS on
steroidogenesis, suggesting that activation of PKC is responsible for the CS-induced steroidogenesis(19).

Cardiovascular Function
Like other medicinal fungi used in Chinese medicine,
the mycelia and fruiting bodies of CS are rich in adenosine.
Mild hypotensive effect and platelet aggregation inhibition
are expected. Vasodilating effect of cultured CS mycelia has
been demonstrated in anesthetized dogs(20). Hot water extract
of CS exhibits negative inotropic effect on guinea-pig right
atrium in vitro(21). CS inhibits the twitch response of guineapig ileum and aggregation of human blood platelet. The
activities are ascribed to the combination of adenosine, 5’AMP, and nucleic acid-related compounds in the extract.
An ethanolic extract (65% ethanol) of CS counteracts
the arrhythmia induced by aconitine or BaCl2 in rats(22). The
extract also increases the tolerant dose of ouabain to produce
the arrhythmias in guinea pigs. It reduces the heart rate of
anesthetic rats, and decreases the contractility of isolated
papillary muscle or atria in guinea pigs. However, it has no
effect on automatic rhythmicity or functional refractory period of the atria. The ethanolic extract of CS mycelium (CsB851) also inhibits thrombus formation in abdominal aorta in
rabbits(23). Aortic thrombosis in de-endotheliazed rabbits and
51Cr labeled autologous platelets were used for the evaluation
of platelet-vessel wall interaction. CsB-851 treatment
reduces the 51Cr labeled platelet number of injured abdominal aorta. It demonstrates that CsB-851 may inhibit thrombus
formation at the de-endotheliazed surface of the aorta. CsB851 inhibits platelet aggregation in vitro but has no effect on
coagulation in vivo. The inhibitory effect of CsB-851 on arterial thrombus formation is related to the inhibition of platelet
function.
A double-blind, randomized placebo-control clinical
trial has been carried out for the treatment of hyperlipidemia
with cultivated Cordyceps(24). No detailed information about
the potential ingredients in Cordyceps preparation is provided to correlate the clinical observations.

Anticancer Activities
The crude methanolic extract of CS fruiting bodies
inhibits the growth of tumor cell lines, namely K562, Vero,
Wish, Calu-1, and Raji cells(25). After further fractionation by
using silica gel column chromatography, two fractions
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(namely CS-36-39 and CS-48-51) significantly inhibit the
growth of these tumor cells. The inhibitory activities are not
due to the polysaccharides, which have been eliminated in
the extraction and chromatographic separation. These two
fractions do not contain cordycepin. This suggests that lowmolecular-weight tumor cell growth inhibitors, other than
cordycepin and polysaccharides, are present in CS.
Antitumor activity of a warm water extract of CS (ECS)
against murine tumor cell lines has been observed(26). Ehrlich
ascites carcinoma cells (EAC) allogeneic to ICR mice and
Meth A fibrosarcoma (Meth A) syngeneic to BALB/c mice
were used as the target tumor cell lines. Animals were inoculated (i.p.) with EAC or Meth A on day 0. ECS was i.p.
injected into mice from day 1 to day 4. ECS-treatment
increases the survival time of the allogeneic mice inoculated
with EAC. More ECS-treated mice survive for 60 days after
EAC implantation than control. ECS-treatment also increases the survival time of the syngeneic mice inoculated with
Meth A. No cytotoxic effect of ECS was found on either
EAC or Meth A in vitro. The antitumor effect of ECS in the
allogeneic mice is reduced when the mice received whole
body X-irradiation (5 Gy) before EAC implantation. This
indicates that the antitumor effect of ECS is mediated
through its immunomodulating action.
Two antitumor sterols, namely 5α, 8α-epidioxy-24(R)methylcholesta-6, 22-dien-3β-D-glucopyranoside and 5, 6epoxy-24(R)-methylcholesta-7, 22-dien-3β-ol have been isolated from the methanolic extract of cultured mycelia of
CS(27). The glycosylated form of ergosterol peroxide at 10
µg/mL inhibits the proliferation of K562, Jurkat, WM-1341,
HL-60 and RPMI-8226 tumor cell lines more potently than
its aglycone, 5α, 8α-epidioxy-24(R)-methylcholesta-6, 22dien-3β-ol.
A polysaccharide fraction of CS (PSCS) stimulates the
proliferation and differentiation of human leukemic U937
cells(28). The conditioned medium from PSCS (10 µg/mL)stimulated blood mononuclear cells (PSCS-MNC-CM)
inhibits the proliferation of U937 cells resulting in a growth
inhibition rate of 78-83%. PSCS-MNC-CM treatment also
induces cells differentiation into mature monocytes/
macrophages that express nonspecific esterase activity,
CD11b, CD14, and CD68. The differentiated U937 cells
maintain functions of phagocytosis and superoxide production. PSCS alone or normal MNC-CM has no such effects.
The levels of IFNγ, TNFα, and IL-1 are greatly increased in
MNC-CM prepared with PSCS stimulation. An antibody
neutralization study indicates that the tumoricidal and differentiating effects of PSCS-MNC-CM are mainly derived from
the elevated cytokines, especially IFNγ and TNFα. These
cytokines synergistically inhibit cell growth and inducing
differentiation. The effects of the ethanolic extract of CS
(CS-II) on murine and human in vitro natural killer cell (NK)
activities, murine in vivo NK activity (by 125I clearance
assay), and colony formation of B16 melanoma in mouse
lungs have been reported(29). The in vivo and in vitro NK
activities of mice are augmented by i.p. injection of CS-II.
The inhibition of NK activity by cyclophosphamide (Cy) is

prevented following the administration of CS-II. In vitro NK
activity of human peripheral blood mononuclear cells
(PBMs) is also elevated by preincubation with CS-II. Colony
formation of B16 melanoma in mouse lungs is reduced by i.p.
pretreatment of animals with CS-II. Potential application of
CS-II as an immunopotentiating agent in treating cancer and
immuno-deficient patients has been suggested.
Down-regulation of the major histocompatibility complex (MHC) antigens of certain tumors may result in an
escape of immune surveillance. CS increases the expression
of MHC class II antigens on human hepatoma cells
(HA22T/VGH)(30). In the study, immunostaining with monoclonal antibody (MAb) L243, against the HLA DR region of
MHC class II antigens on human hepatoma cells was analyzed by using flow cytofluorimetry. The degree of fluorescence intensity on L243(+) cells was expressed as relative
mean fluorescence intensity (RMFI). A methanolic extract of
CS (VGH-CS-ME-82) increases MHC class II antigen
expression on HA22T/VGH cells with an increase in the percentage of L243(+) cells. VGH-CS-ME-82, either alone or
with IFNγ induction, increases the MHC class II antigen
expression and makes the host immune surveillance more
effective against tumor cells with down-regulated MHC class
II antigen expression.
The water extract of CS (WECS) inhibits spontaneous
liver metastasis of Lewis lung carcinoma (LLC) and B16
melanoma cells in syngeneic mice (C57BL/6J)(31). Animals
were given an s.c. injection of LLC and B16 cells and sacrificed 20 and 26 days after tumor inoculation, respectively.
WECS was administered daily (p.o. 100 mg/kg bw) in the
experiment of LLC and in a dose of 100 or 200 mg/kg bw. in
the experiment of B16 from one week before tumor inoculation. The relative liver weight of tumor-inoculated mice
increases due to tumor metastasis. CS treatment reduces the
liver weight in both LLC and B16 experiments indicating
that CS has an anti-metastatic activity that is not due to
cordycepin. Inhibitory effects of Cordyceps on carcinogenesis of the forestomach in mice(32) and antitumor activities of
CS and cultured Cordyceps mycelia(33) on Lewis lung cancer
of mice(34) have also been demonstrated.
In a clinical study, the effect of Jinshuibao capsule
(JSBC) (a preparation reported to contain the active principles and pharmacological activity of CS) on the immunologic function of 36 patients with advanced cancer has been
reported(35). JSBC restores cellular immunologic function
and improves quality of life, but has no effect on the humoral
immunologic function. Detailed information about the cancer
type and therapy, other than JSBS, is not described. The
report suggests that CS preparation, if properly formulated,
may be used as an adjuvant therapy for advanced cancer.

Immunomodulation
Both immunosuppressive and immuno-stimulating
functions of CS have been observed. The effects of low-molecular-weight part of CS (methanolic extract and further column fractions) on the lymphoproliferative response, natural
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killer (NK) cell activity, and phytohemagglutinin (PHA)stimulated interleukin-2 (IL-2) and tumor necrosis factoralpha (TNF-α) production on human mononuclear cells
(HMNC) have been elucidated(36). Two such fractions (CS36-39 and CS-48-51) inhibited the blastogenesis response,
NK cell activity, and IL-2 production of HMNC stimulated
by PHA. TNF-α production in HMNC culture is reduced by
treatment with CS-36-39 and CS-48-51 indicating that CS
contains immuno-suppressive ingredients.
The effects of CS on murine T lymphocyte subsets have
been reported(37). A preparation of CS (Cs-Cr) increases the
number of T helper cells and Lyt-1/Lyt-2 (T helper to T suppressor cell) ratio in peripheral blood and spleen. The spleen
weight, phagocyte counts, and phagocytic activity are elevated. Cs-Cr protects T helper cells from the immunosuppressive effects of prednisolone acetate and cyclophosphamide. It
suggests that Cs-Cr is an immunoregulator of cellular immunity and may be useful in immuno-deficient or immuno-suppressed patients. The immunosuppressive effect of cultured
CS on cellular immune response has been further demonstrated in vitro and in vivo(38). CS (0.6 to 5 mg/mL) inhibits
the following immune reactions of mice in a dose-dependent
manner: phagocytic function of peripheral blood leucocytes,
mitogenic response of spleen lymphocytes to Con A, and
mixed lymphocyte culture and LPS-induced IL-1 release of
macrophages. The survival rate of mice spleen lymphocytes
cultured with CS is also increased. CS treatment (4 g/kg/d)
prolongs the mice skin allograft survival time. The immunosuppressive activity of CS is estimated to be close to that of
cyclosporin A (5 mg/kg/d) on skin allograft(39).
CS also has an immunosuppressant effect in the heterotopic heart allograft model in rats(40). The inhibitory effect of
a CS preparation (CS-1) on the immune response responsible
for the organ transplant rejection has been studied. CS-1 prolongs heterotopic heart allograft survival in rats with an effect
similar to those of cyclosporin A and glucocorticoid. The
study suggests that CS can be a promising immunosuppressant in clinical organ transplantation in the future.
Systemic lupus erythematosus (SLE) is an autoimmune
disease with multiple organ system involvement. CS
improves survival and inhibits anti-ds DNA antibody production in lupus mice (NZB/NZW F1). CS also improves the
defective IL-2 production in vitro in SLE patients. CS may
have great future potential for the management of human
SLE(41).
Augmentation of various immune activities of tumorbearing hosts with an extract of CS (CSE) has been reported(42). C57BL/6 mice implanted subcutaneously with syngeneic EL-4 lymphoma cells were employed as the host. Oral
administration of CSE reduces tumor size and prolongs the
host survival time. As judged by plaque-forming cells against
T-dependent (sheep erythrocytes) and T-independent (bacterial LPS) antigens, CSE augments the antibody responses.
Chemotaxis of peritoneal macrophages is determined within
a few days after EL-4 transplantation. Treatment with CSE,
at -14, -7, -4, +4, +7 and +10 days after the tumor transplantation, augments the activity by 4-folds. Phagocytic activity

of macrophages is decreased in tumor-bearing mice treated
with cyclophosphamide 3 and 5 days after tumor transplantation. CSE restores the activity to more than the normal level.
CSE also protects against systemic infection by Salmonella
enteritides. The tumor-bearing mice receiving CSE live
longer than control groups. Additional studies support that
the pharmacological actions of CS on murine immune
organs, such as CS action after irradiation with 60Co gammaray, are mainly mediated through the host immune system(4245). In summary, the effects of natural CS and its cultured
mycelia on murine immuno-organs, the function of the
mononuclear macrophage system, and cellular immunity
have been demonstrated in many studies(46-48).
Several clinical studies have been carried out to investigate the potential of CS on declined immune function. The
effects of CS on peripheral NK cells from healthy persons
and leukemia patients have been studied(49). CS treatment
augments NK cell activity and increases CD16 expression in
lymphocytes and the binding capacity to K562 cells. CS as an
adjunct therapy in the treatment of leukemia has been suggested(49). The modulating effect of CS on T-lymphocyte
subsets in chronic renal failure also deserves attention(50). In
a clinical study, synchronous measurement of renal function
and T-cell subsets were taken in patients of chronic renal failure (CRF) (n=51). Patients (n=28) taking CS (3-5 g/d) were
considered as a study group. A significant decrease of OKT3,
OKT4, OKT4/OKT8 was found in CRF indicating that cellular immune function is decreased in CRF. CS treatment
improves renal function and increases the OKT4 and
OKT4/OKT8 ratio (50). The study indicates that CS may
improve renal function and simultaneously enhance the cellular immune function in CRF.

Polysaccharides and Their Biological Activities
Fungal polysaccharides are commonly recovered from
the fruiting bodies and cultured mycelia by aqueous extraction at elevated temperature, followed by ethanol precipitation. Many polysaccharides with antitumor, immunomodulatory, and hypoglycemic activities have been isolated from
Chinese medicinal fungi and related species, including
Ganoderma, Cordyceps, Auricularia, and Poria(51). The isolation of hypoglycemic polysaccharides from the cultural
mycelium of CS has been reported(52). Intraperitoneal (i.p.)
injection of crude polysaccharides, obtained from a hot-water
extract and alkaline extracts of CS mycelium, shows hypoglycemic activities in normal and streptozotocin (STZ)induced diabetic mice but slightly reduces the plasma glucose in normal mice by oral administration. Oral administration of (50 mg/kg) of CS-OHEP, a crude polysaccharide
preparation obtained from 5% sodium hydroxide extraction,
reduces plasma glucose without affecting plasma insulin
level in normal mice. A neutral polysaccharide (CS-F30;
MW about 45 kDa) exhibited higher hypoglycemic activity
than CS-OHEP by i.p. injection. CS-F30 is composed of
galactose, glucose, and mannose in molar percent of
62:28:10. CS-F30 exhibits a hypoglycemic activity in genet-
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ic diabetic mice after i.p. administration. It also quickly
reduces plasma glucose in normal and STZ-induced diabetic
mice after i.v. administration. Administration of CS-F30 to
normal mice increases hepatic glucokinase, hexokinase and
glucose-6-phosphate dehydrogenase activities and reduces
hepatic glycogen content. CS-F30 also lowers the plasma triacylglycerol and cholesterol levels in mice(53).
Pharmacology and structural information of polysaccharides derived from species of genus Cordyceps other than
C. sinensis deserve great attention. Two bioactive galactomannans (CI-P and CI-A), isolated from the insect body
portion of Chan hua (Cordyceps cicadae), have been studied
in detail(54). CI-P having low affinity for Con A exhibits carbon-clearance activity in mice. CI-P and CI-A have little
antitumor activity against sarcoma 180 in mice but have
hypoglycemic activities in normal mice.
A water-insoluble, alkali-soluble extracellular glucan
(CO-1) (average MW about 632 kDa) has been isolated from
Cordyceps ophioglossoides(55). 1H- and 13C-NMR and IR
spectral data indicate that the glucosidic linkages in CO-1 are
beta. CO-1 is composed of a backbone of (1-3)-linked β-Dglucopyranosyl residues with a β-D-glucopyranosyl group
attached to O-6 of every second D-glucopyranosyl residue of
the backbone. CO-1 inhibits the growth of Sarcoma 180
solid-type tumor(56).
Gal β-(1-3) GalNAc-Ser/Thr occurs in the linkage
region of the polygalactosamine containing glycoprotein
from C. ophioglossoides(57). Deamination by nitrous acid liberates the N-acetyl galactosamine containing glycoproteins
from galactosminoglycan (CO-N) which has been isolated
from C. ophioglossoides culture. Mild alkaline borohydride
degradation of the purified glycoprotein releases oligosaccharide alditols. The smallest oligosaccharide alditol has
been characterized to be Gal β-(1-3) GalNAcol. It indicates
that the polygalactosamine part is attached to the protein part
via Gal beta (1-3) GalNAc-Ser/Thr as the linkage.
Antitumor activity of a protein-bound polysaccharide
fraction (SN-C) from C. ophioglossoides has been demonstrated in mice(58). In transplanted allogeneic and syngeneic
murine tumor models, i.p. administration of SN-C suppresses the tumor growth of sarcoma-180. SN-C also prolongs the
life span of ICR mice inoculated (i.p.) with Ehrlich carcinoma, and C3H/He mice inoculated with a syngeneic tumor (X5563). SN-C has no effect on delayed-type hypersensitivity
(DTH) in normal mice, but can restore the depressed capacity to raise DTH in tumor-bearing mice indicating that SN-C
exerts direct and host-mediated antitumor effects(59). The
galactosaminoglycan moiety (CO-N) has been obtained from
an antitumor polysaccharide fraction (SN-C) produced by C.
ophioglossoides(60). After sonication of SN-C, CO-N can be
isolated by precipitation with 10% ammonium hydroxide.
When given i.p. to mice, CO-N inhibits the proliferation of
sarcoma 180 cells inoculated into the peritoneal cavity and
has a life-prolonging effect against ascitic tumors such as
Ehrlich carcinoma and IMC carcinoma. CO-N inhibits solid
Ehrlich carcinoma when given intratumorally and also
inhibits the growth of a syngeneic solid tumor (MM46 mam-

mary carcinoma) upon iv administration. CO-N has a cytocidal effect against cultured IMC and P388D1 cells. CO-N
exhibits a broad MW distribution with an average MW of 33
kDa(61). The low-MW fraction (MW<6600 Da) has a weak
antitumor activity. Depolymerized CO-N (ca. 5500 Da),
obtained by extensive ultrasonication of CO-N, retains the
antitumor activity of CO-N against Ehrlich ascitic carcinoma
and MM46 solid mammary carcinoma.

Erythropoiesis and Hemopoiesis
CS stimulates erythropoiesis in mouse bone marrow(62).
A preparation of CS (CS-Cr) stimulates proliferation of erythroid progenitor cells (CFU-E and BFU-E) in LACA mouse
marrow in vivo and in vitro. The numbers of CFU-E and
BFU-E increase after a 5-day treatment with CS-Cr (100, 150
and 200 mg/kg). Higher doses (> 150 mg/kg) result in a
reduction of the peak of CFU-E and BFU-E. Ara-C increases
in the percentage of CFU-E and BFU-E cells in S-phase after
CS-Cr treatment. Pretreatment of mice with CS-Cr protects
CFU-E and BFU-E against harringtonine (a cytotoxic agent).
Addition of CS-Cr (150-200 µg/mL) to culture system stimulates the generation of CFU-E and BFU-E in vitro. The
stimulatory action of CS-Cr on fibroblast colony-forming
units (CFU-F) proliferation has been observed in vivo and in
vitro(62). Platelet hemopoiesis and ultrastructure changes in
mice treated with natural CS and cultured mycelia have also
been observed(63).

Natural Product Chemistry and Pharmacological
Functions
Many natural products have been identified from the
fruiting bodies and cultured mycelium of Cordyceps and
related species. The chemical constituents (64) including
sterols and their glucosides, nucleosides, polysaccharides in
CS have been reported(25, 27, 65). Reversed-phase HPLC is the
most common tool used for the comparison of chemical constituents of CS and related species, such as Cordyceps barnesii(66) and Cordyceps mililaris(67, 68). Ophiocordin, originally
isolated from Cordyceps ophioglossoides(69), has been found
to be identical to the potent protein kinase C (PKC) inhibitor
balanol from the fungus Verticillium balanoides (70) .
Production of cordycepin (3’-deoxyadenosine) in Cordyceps
militaris has been reported since 1964(71, 72). The metabolic
fate of adenosine and cordycepin in cordycepin biosynthesis
has been conducted in C. militaris(73). However, the content
of cordycepin in CS is either very low or not detectable(74).

CONCLUSION
Many studies in vitro and in vivo support that Cordyceps
sinensis has diverse biological activities and pharmacological potential (Table 1). The effects in renal and hepatic function and immunomodulation-related antitumor activities are
most promising and deserve great attention. Although the
origin and preparation of Cordyceps are not always clearly
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addressed in publications, most studies use water-soluble,
polysaccharide-rich fractions or alcohol extracts. Many studies use fruiting bodies as the part of investigation. However,
recently an increasing number of studies have used cultured
mycelia. It is difficult to determine if the same bioactive
ingredients exist in fruiting bodies and cultured mycelia in
these pharmacological studies. Future study of this medicinal
fungus greatly depends on the use of chemically defined and
pharmacology-proven fungal materials. Fermented mycelia,
which can be constantly produced in a large scale, are a better source of this herbal medicine. More mechanism-based,
disease-oriented pharmacological studies are required to
ensure clinical application. Furthermore, adjuvant therapy of
Cordyceps sinensis in immune function disturbances, cancer,
and renal failure is a possibility.
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摘

要

冬蟲夏草是一種使用於傳統中國醫藥上的蟲生真菌，具有廣泛的生物活性，並特別表現在腎臟、肝臟、
心血管、免疫系統方面的藥理功能。蟲草菌的藥理作用主要是因為冬蟲夏草及相關真菌可產生具有生物活性
的多醣體、修飾型核啟及環胞素型的代謝物所致。冬蟲夏草的藥理作用亦因而以在腎與肝功能及免疫調節上
的表現最值得關注。先前的研究多採用子實體為藥材，最近的藥理作用研究報告中，採用培養菌絲體為對象
者已逐漸增多。然而，目前並無法依文獻資料判斷子實體與菌絲是否均產生相同有效成份而導致其藥理效
果。未來宜有更多疾病導向且以作用機轉為基礎的藥理學研究，以強化冬蟲夏草用於特定疾病的臨床基礎。
目前資料顯示，若能再於雙盲、隨機且安慰劑控制組之臨床試驗顯示有效，則冬蟲夏草最可能使用於免疫功
能變異、癌症、腎功能衰敗的輔助治療方面。
關鍵詞：冬蟲夏草，抗癌活性，肝功能，腎功能，免疫調節，多醣體，修飾型核啟

